Article

FDA Oks single-use vial of hyaluronidase

Irvine, CA-The FDA has approved the single-use vial of ISTA Pharmaceuticals' hyaluronidase injection ovine sterile solution (Vitrase) for use as a spreading agent in the dispersion and absorption of other drugs. The company said it would launch the new vial size and the larger 6,200-USP Units multi-purpose vial early in the first quarter of 2005. The larger vial was approved in May.

Irvine, CA-The FDA has approved the single-use vial of ISTA Pharmaceuticals' hyaluronidase injection ovine sterile solution (Vitrase) for use as a spreading agent in the dispersion and absorption of other drugs. The company said it would launch the new vial size and the larger 6,200-USP Units multi-purpose vial early in the first quarter of 2005. The larger vial was approved in May.

Meanwhile, ISTA Pharmaceuticals has licensed exclusive U.S. marketing rights from Senju Pharmaceuticals Co. to ecabet sodium, a prescription eye drop for the treatment of dry eye. The product, which is said to stimulate mucin secretion and improve the quality of tears, is in phase II studies in Japan. It is on the market there as an oral agent for gastric ulcers and gastritis.

ISTA already has marketing agreements with Senju for once-daily timolol (Istalol) and bromfenac sodium ophthalmic solution 0.1% (Xibrom).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.